238 related articles for article (PubMed ID: 25618421)
1. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
[TBL] [Abstract][Full Text] [Related]
2. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
[TBL] [Abstract][Full Text] [Related]
3. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
Mendes RE; Flamm RK; Farrell DJ; Sader HS; Jones RN
J Chemother; 2016 Apr; 28(2):83-8. PubMed ID: 26058844
[TBL] [Abstract][Full Text] [Related]
4. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2015 Jan; 59(1):702-6. PubMed ID: 25348529
[TBL] [Abstract][Full Text] [Related]
5. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
Mendes RE; Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2012 Jan; 72(1):113-7. PubMed ID: 22078909
[TBL] [Abstract][Full Text] [Related]
6. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.
Pfaller MA; Sader HS; Flamm RK; Castanheira M; Smart JI; Mendes RE
Microb Drug Resist; 2017 Sep; 23(6):718-726. PubMed ID: 28727951
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):417-22. PubMed ID: 23514757
[TBL] [Abstract][Full Text] [Related]
10. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Karlowsky JA; Nichol K; Zhanel GG
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
[TBL] [Abstract][Full Text] [Related]
12. Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.
Jones RN; Flamm RK; Castanheira M; Sader HS; Smart JI; Mendes RE
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):184-187. PubMed ID: 28377166
[TBL] [Abstract][Full Text] [Related]
13. Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014).
Mendes RE; Sader HS; Smart JI; Castanheira M; Flamm RK
Eur J Clin Microbiol Infect Dis; 2017 Jun; 36(6):1013-1017. PubMed ID: 28111724
[TBL] [Abstract][Full Text] [Related]
14. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
Jansen WT; Verel A; Verhoef J; Milatovic D
Antimicrob Agents Chemother; 2007 Sep; 51(9):3420-4. PubMed ID: 17606689
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.
Malli E; Spiliopoulou I; Kolonitsiou F; Klapsa D; Giannitsioti E; Pantelidi K; Pratti A; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Frantzidou F; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou ED; Petinaki E
Int J Antimicrob Agents; 2008 Dec; 32(6):525-8. PubMed ID: 18774268
[TBL] [Abstract][Full Text] [Related]
18. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
Putnam SD; Sader HS; Moet GJ; Mendes RE; Jones RN
Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
[TBL] [Abstract][Full Text] [Related]
19. Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013).
Mendes RE; Sader HS; Flamm RK; Farrell DJ; Jones RN
J Glob Antimicrob Resist; 2015 Mar; 3(1):36-39. PubMed ID: 27873648
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial Activity of Telavancin Tested
Duncan LR; Sader HS; Huband MD; Flamm RK; Mendes RE
Microb Drug Resist; 2020 Aug; 26(8):934-943. PubMed ID: 32049591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
